IRVINE, Calif.--(BUSINESS WIRE)--TAE Life Sciences (TLS), a leader in developing boron neutron capture therapy (BNCT) technology and associated innovative boron target drugs, and Stella Pharma, the pioneering developer of boronophenylalanine (BPA) under the product name Steboronine® for BNCT, are pleased to announce a strategic collaboration focused on the development, commercialization and expansion of BNCT using BPA in the United States and European markets..

加利福尼亚州欧文市（商业新闻短讯）--TAE生命科学（TLS）是开发硼中子俘获疗法（BNCT）技术和相关创新硼靶向药物的领导者，Stella Pharma是硼苯丙氨酸（BPA）的先驱开发商，产品名为Steboronine®，用于BNCT，很高兴宣布一项战略合作，重点是在美国和欧洲市场使用BPA开发，商业化和扩展BNCT。。

Stella Pharma’s BPA drug is the world’s first and only clinically approved boron drug for BNCT, marking a breakthrough in cancer treatment. Japan became the first country to approve BNCT for the treatment of head and neck cancers, using Stella Pharma’s pioneering BPA drug. Now, Stella Pharma, as the leading producer and supplier of BPA, has joined forces with TAE Life Sciences to expand the adoption of BNCT worldwide..

Stella Pharma的BPA药物是世界上第一种也是唯一一种临床批准用于BNCT的硼药物，标志着癌症治疗取得了突破。日本成为第一个使用Stella Pharma首创的BPA药物批准BNCT治疗头颈部癌症的国家。现在，Stella Pharma作为BPA的主要生产商和供应商，已与TAE Life Sciences联手，在全球范围内扩大BNCT的采用。。

Supporting the Future of BNCT Therapy

支持BNCT治疗的未来

The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026. TLS will serve as the exclusive commercial partner for Stella Pharma’s BPA in these regions, representing a significant expansion of BNCT accessibility outside of Asia..

合作目标包括在美国和欧洲开展BNCT和BPA开发和商业化方面的广泛国际合作，临床试验预计将于2026年开始。TLS将作为Stella Pharma BPA在这些地区的独家商业合作伙伴，代表着BNCT在亚洲以外的可访问性的显着扩展。。

“Our partnership with Stella Pharma combines our shared commitment to advancing BNCT as a viable cancer treatment for patients worldwide,” said Rob Hill, CEO of TAE Life Sciences. “We are excited to bring the proven benefits of BPA to U.S. and European healthcare institutions and to support BNCT globally with this powerful therapeutic solution.”.

TAE生命科学首席执行官Rob Hill说：“我们与Stella Pharma的合作关系结合了我们共同的承诺，即推动BNCT成为全球患者可行的癌症治疗方法。”。“我们很高兴能为美国和欧洲的医疗机构带来经证实的BPA益处，并用这种强大的治疗方案在全球范围内支持BNCT。”。

Both companies have also committed to supporting BNCT equipment vendors across all markets in implementing BPA-based BNCT treatments. By fostering partnerships within the BNCT ecosystem, TLS and Stella Pharma aim to enhance the clinical reach of BNCT in treating recurrent head and neck cancers and advancing clinical studies for other cancers, including brain, skin, breast, esophagus, and lung cancers..

两家公司还承诺支持所有市场的BNCT设备供应商实施基于BPA的BNCT治疗。通过在BNCT生态系统内建立伙伴关系，TLS和Stella Pharma旨在增强BNCT在治疗复发性头颈癌方面的临床影响力，并推进其他癌症（包括脑癌，皮肤癌，乳腺癌，食道癌和肺癌）的临床研究。。

“Our alliance with TAE Life Sciences marks a significant step in expanding the reach of BPA-based BNCT treatments beyond Asia,” said Koki Uehara, President and Chief Operating Officer of Stella Pharma. “We look forward to collaborating internationally to develop and commercialize BNCT and aim to deliver these advancing cancer treatments to patients and their families worldwide.”.

Stella Pharma总裁兼首席运营官Koki Uehara表示：“我们与TAE Life Sciences的联盟标志着将基于BPA的BNCT治疗范围扩大到亚洲以外的重要一步。”。“我们期待着开展国际合作，开发BNCT并将其商业化，旨在为全球患者及其家属提供这些先进的癌症治疗方法。”。

Exploring Future Opportunities Together

共同探索未来的机会

Stella Pharma and TAE Life Sciences share a vision of advancing BNCT treatment for hard-to-treat cancers and pledge to explore additional areas for collaboration. Through this alliance, they seek to accelerate innovation, expand treatment options, and ultimately improve outcomes for cancer patients worldwide..

Stella Pharma和TAE Life Sciences共同致力于推进难治性癌症的BNCT治疗，并承诺探索其他合作领域。。。